Osteoarthritis - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Osteoarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Osteoarthritis: Overview
Osteoarthritis (also known as OA) is a common joint disease that most often affects middle-age to elderly people. It is commonly referred to as 'wear and tear' of the joints, but we now know that OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments, and bone. Although it is more common in older people, it is not really accurate to say that the joints are just “wearing out.” It is characterized by breakdown of the cartilage (the tissue that cushions the ends of the bones between joints), bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining (called the synovium). OA is a top cause of disability in older people. The goal of osteoarthritis treatment is to reduce pain and improve function. There is no cure for the disease, but some treatments attempt to slow disease progression.
'Osteoarthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteoarthritis Emerging Drugs
Further product details are provided in the report……..
Osteoarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:
Osteoarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.
Osteoarthritis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Osteoarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Osteoarthritis: Overview
Osteoarthritis (also known as OA) is a common joint disease that most often affects middle-age to elderly people. It is commonly referred to as 'wear and tear' of the joints, but we now know that OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments, and bone. Although it is more common in older people, it is not really accurate to say that the joints are just “wearing out.” It is characterized by breakdown of the cartilage (the tissue that cushions the ends of the bones between joints), bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining (called the synovium). OA is a top cause of disability in older people. The goal of osteoarthritis treatment is to reduce pain and improve function. There is no cure for the disease, but some treatments attempt to slow disease progression.
'Osteoarthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.
This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteoarthritis Emerging Drugs
- Ampion: Ampio Pharmaceuticals
- Lorecivivint (SM04690): Biosplice Therapeutics
Further product details are provided in the report……..
Osteoarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Osteoarthritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Osteoarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.
Osteoarthritis Report Insights
- Osteoarthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Osteoarthritis drugs?
- How many Osteoarthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoarthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Osteoarthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ampio Pharmaceuticals
- Biosplice Therapeutics
- Symic Bio
- UnicoCell Biomed CO. LTD
- Eupraxia Pharmaceuticals Inc.
- Eli Lilly and Company
- Xalud Therapeutics, Inc.
- ICM Biotech Australia Pty Ltd.
- Taiwan Liposomal Company
- Gwo Xi Stem Cell Applied Technology Co., Ltd.
- K-STEMCELL
- Centrexion Therapeutics
- Techfields Pharma
- AstraZeneca
- Merck KGaA
- Novartis
- Antibe Therapeutics Inc.
- Bioventus LLC
- PMG Pharm Co., Ltd
- Meluha Life Sciences SDN BHD
- Anika Therapeutics
- MiMedx Group, Inc.
- Medivir
- Orient Europharma Co., Ltd.
- HSRx Biopharmaceutical
- Meiji Seika Pharma
- Peptinov
- Atlanthera
- Yuhan
- OrthoTrophix
- CartilaGen
- Ampion
- Lorecivivint (SM04690)
- SB-061
- Elixcyte
- V120083
- Tanezumab
- XT-150
- ICM-203
- TLC599
- GXCPC1
- JointStem
- CNTX-4975-05
- X0002
- MEDI7352
- M6495
- LNA043
- ATB-346
- PTP-001
- PK101
- Chondrogen
- Cingal
- Micronized DHACM
- MIV-711
- 2ccPA
- PPV 06
- 1102-11
- YH 23537
- TPX 100
- CG 001
Introduction
Executive Summary
Osteoarthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ampion: Ampio Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LNA 043: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PPV 06: Peptinov
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
CG 001: CartilaGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Osteoarthritis Key Companies
Osteoarthritis Key Products
Osteoarthritis- Unmet Needs
Osteoarthritis- Market Drivers and Barriers
Osteoarthritis- Future Perspectives and Conclusion
Osteoarthritis Analyst Views
Osteoarthritis Key Companies
Appendix
Executive Summary
Osteoarthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ampion: Ampio Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LNA 043: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PPV 06: Peptinov
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
CG 001: CartilaGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Osteoarthritis Key Companies
Osteoarthritis Key Products
Osteoarthritis- Unmet Needs
Osteoarthritis- Market Drivers and Barriers
Osteoarthritis- Future Perspectives and Conclusion
Osteoarthritis Analyst Views
Osteoarthritis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Osteoarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Osteoarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Osteoarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Osteoarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
